Back to search results

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Abroad (travel likely)RecruitingPHASE1

Conditions

B-cell Acute Lymphoblastic Leukemia · Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Wendy Stock, MD) · 855-702-8222

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Marlise R Luskin, MD)
    Contact: Principal Investigator (Marlise Luskin, MD)

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Jessica Liegel, MD)

  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

    Contact: Study coordinator (Eunice Wang, MD) · 716-845-2300
Study leads

  • Marlise R. Luskin, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)